BAKER BROS. ADVISORS LP bought VTVT

Footnotes

Pursuant to a securities purchase agreement (the "SPA") entered into between vTv Therapeutics Inc. (the "Issuer") and 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences" and together with 667, the "Funds") and other institutional investors, the Issuer agreed to issue and sell and 667 and Life Sciences agreed to acquire in a private placement ("Private Placement") that closed on September 3, 2025 221,452 and 2,400,605 units (the "Units"), respectively, each Unit comprised of (i) (A) one share of the Issuer's Class A Common Stock ("Common Stock") or (B) a prefunded warrant to purchase Common Stock at an exercise price of $0.01 per share with no expiration date ("Prefunded Warrants") and (ii) a warrant (the "Common Warrants") to purchase, at the holder's election, either one share of Common Stock or a Prefunded Warrant.; The Units were sold at a per-Unit price of (x) $15.265, in the case of Units including a share of Common Stock, and (y) $15.255, in the case of Units including a Prefunded Warrant.; Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds.; Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.; After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I or securities reported in column 9 of Table II directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.